Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM53IPE)

Drug Name
SAR425899 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 1 [1]
Type-2 diabetes 5A11 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM53IPE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon (GCG) TT0NUFM GLUC_HUMAN Agonist [2]
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Modulator [3]
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 2 2.848 3.472 2.963
Glucagon receptor (GCGR) DTT GCGR 4.695 1.926 1.322 3.797
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Glucagon receptor (GCGR) DTT GCGR 7.24E-02 -0.52 -0.92
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02411825) Multiple Ascending Dose Study in Healthy Male Subjects. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Company report (Sanofi) (drug: LIXisenatide)